



Atty.  
Dkt. No.

056707-5001-01

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned Group Art Unit: 1645

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Page 1 of 19

U.S. PATENT DOCUMENTS						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
UPK	aa 3,837,340	09/1974	COUNTER			
	ab 3,948,263	04/1976	DRAKE			
	ac 3,982,536	09/1976	KROGSENG			
	ad 4,196,191	04/1980	ALMEIDA			
	ae 4,220,584	09/1980	LIMJUCO			
	af 4,235,871	11/1980	PAPAHADJOPOULOS			
	ag 4,285,931	08/1981	LIMJUCO			
	ah 4,394,448	07/1983	SZOKA			
	ai 4,411,888	10/1983	KLIPSTEIN			
	aj 4,455,142	06/1984	MARTINS			
	ak 4,484,923	11/1984	AMKRAUT			
	al 4,497,796	02/1985	SALSER			
	am 4,587,044	05/1986	MILLER			
	an 4,692,482	09/1987	BANERJEE			
	ao 4,725,271	02/1988	KOROL			
	ap 4,732,892	03/1988	SARPOTDAR			
	aq 4,743,588	05/1988	MIREJOVSKY			
	ar 4,761,372	08/1988	MAAS			
	as 4,764,381	08/1988	BODOR			
	at 4,783,450	11/1988	FAWZI			
	au 4,834,985	05/1989	ELGER			
	av 4,876,278	10/1989	TAYLOR			
	aw 4,877,612	10/1989	BERGER			
	ax 4,892,737	01/1990	BODOR			
	ay 4,908,389	03/1990	MAHJOUR			
	az 4,917,688	04/1990	NELSON			

FOREIGN PATENT DOCUMENTS							English Abstract		Translation Readily Available	
Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass		Enclosed	No	Enclose	No

OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)										

Examiner: [Signature] Date Considered: 6/20/05  
 \*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

056707-5001-01
----------------

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Page 2 of 19

Examiner: Not Assigned Group Art Unit: 1645

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
UPK	ba 4,917,895	04/1990	LEE			
	bb 4,921,757	05/1990	WHEATLEY			
	bc 4,929,442	05/1990	POWELL			
	bd 4,946,853	08/1990	BANNON			
	be 4,956,171	09/1990	CHANG			
	bf 4,960,771	10/1990	RAJADHYAKSHA			
	bg 4,970,206	11/1990	ALEXANDER			
	bh 5,008,050	04/1991	CULLIS			
	bi 5,008,111	04/1991	BODOR			
	bj 5,023,252	06/1991	HSIEH			
	bk 5,028,435	07/1991	KATZ			
	bl 5,030,629	07/1991	RAJADHYAKSHA			
	bm 5,032,402	07/1991	DIGENIS			
	bni 5,041,439	08/1991	KASTING			
	bo 5,045,317	09/1991	CHESS			
	bp 5,049,386	09/1991	EPPSTEIN			
	bq 5,049,387	09/1991	AMKRAUT			
	br 5,059,189	10/1991	CILENTO			
	bs 5,059,421	10/1991	LOUGHREY			
	bt 5,069,904	12/1991	MASTERSON			
	bu 5,082,866	01/1992	WONG			
	bv 5,108,921	04/1992	LOW			
	bw 5,142,044	08/1992	MINASKANIAN			
UPK	bx 5,162,315	11/1992	RAJADHYAKSHA			
	by 5,164,406	11/1992	HELMAN			

**FOREIGN PATENT DOCUMENTS**

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						Enclose	No

OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.):

--

Examiner: *[Signature]* Date Considered: 3/20/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty. Okt. No.	056707-5001-01	Client Ref. No.
-------------------	----------------	-----------------

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicants: GLENN et al.	
Appln. No. 10/790,715	
Filing Date: March 3, 2004	
Examiner: Not Assigned	Group Art Unit: 1645

Page 3 of 14/19

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
ca	5,166,320	11/1992	WU			
cb	5,169,637	12/1982	LENK			
cc	5,182,109	01/1993	TAMURA			
cd	5,196,410	03/1993	FRANCOEUR			
ce	5,200,393	04/1993	WEINER			
cf	5,204,339	04/1993	MINASKANIAN			
cg	5,215,520	06/1993	SHROOT			
ch	5,225,182	07/1993	SHARMA			
ci	5,232,935	08/1993	COLAS			
cj	5,234,959	08/1993	MINASKANIAN			
ck	5,238,944	08/1993	WICK			
cl	5,240,846	08/1993	COLLINS			
cm	5,252,334	10/1993	CHIANG			
cn	5,256,422	10/1993	ALBERT			
co	5,260,066	11/1993	WOOD			
cp	5,270,346	12/1993	MINASKANIAN			
cq	5,308,835	05/1994	CLEMENTS			
cr	5,326,566	07/1994	PARAB			
cs	5,326,790	07/1994	THORNFELDT			
ct	5,328,470	07/1994	NABEL			
cu	5,332,576	07/1994	MANTELLE			
cv	5,332,577	07/1994	GERTNER			
cw	5,340,588	08/1994	DOMB			
cx	5,352,449	10/1994	BELTZ			
cy	5,399,346	03/1995	ANDERSON			
cz	5,411,738	05/1995	HIND			

**FOREIGN PATENT DOCUMENTS**

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						Enclose	No

**OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

Examiner	Date Considered:
----------	------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

Glenn, et al.  
056707-5001-01

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Applicants: GLENN et al.

Appln. No.: 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assign. Group Art Unit: 1645

Page 4 of 19

U.S. PATENT DOCUMENTS						
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Filing Date (if appropriate)
URK	da	5,428,132	06/1995	HIRSCH		
	db	5,445,611	08/1995	EPPSTEIN		
	dc	5,458,140	10/1995	EPPSTEIN		
	dd	5,462,743	10/1995	TURNER		
	de	5,464,386	11/1995	HOFMANN		
	df	5,472,946	12/1995	PECK		
	dg	5,482,965	01/1996	RAJADHYAKSHA		
	dh	5,492,698	02/1996	VON KLEINSORGEN		
	di	5,505,956	04/1996	KIM		
	dj	5,505,958	04/1996	BELLO		
	dk	5,533,995	07/1996	CORISH		
	dl	5,534,260	07/1996	PETERSEN		
	dm	5,536,263	07/1996	ROLF		
	dn	5,540,931	07/1996	HEWITT		
	do	5,547,932	08/1996	CURIEL		
	dp	5,573,778	11/1996	TERRIAULT		
	dq	5,578,475	11/1996	JESSEE		
	dr	5,580,859	12/1996	FELGNER		
	ds	5,589,466	12/1996	FELGNER		
	dt	5,593,972	01/1997	WEINER		
	du	5,601,827	02/1997	COLLIER		
	dv	5,607,691	03/1997	HALE		
	dw	5,612,382	03/1997	FIKE		
	dx	5,614,212	03/1997	D'ANGELO		
	dy	5,614,503	03/1997	CHAUDHARY		
	dz	5,620,896	04/1997	HERMANN		

FOREIGN PATENT DOCUMENTS							English Abstract		Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	Enclosed	No	Enclose	No

OTHER (including in this order: Author, Title, Periodical Name, Date, Reprint, Pages, etc.)

Examiner: *[Signature]* Date Considered: *8/20/05*

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

056707-5001-01

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Page 5 of 149

Examiner: Not Assigned Group Art Unit: 1645

U.S. PATENT DOCUMENTS							
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
GJK	ea	5,626,866	05/1997	EBERT			
	eb	5,643,578	07/1997	ROBINSON			
	ec	5,658,587	08/1997	SANTUS			
	ed	5,661,025	08/1997	SZOKA			
	ee	5,661,130	08/1997	MEEZAN			
	ef	5,674,503	10/1997	OLAFSON			
	eg	5,676,954	10/1997	BRIGHAM			
	eh	5,679,647	10/1997	CARSON			
	ei	5,686,100	11/1997	WILLE			
	ej	5,693,024	12/1997	FLOWER			
	ek	5,693,622	12/1997	WOLFF			
	el	5,695,991	12/1997	LINDHOLM			
	em	5,697,901	12/1997	ERIKSSON			
	en	5,698,416	12/1997	WOLF			
	ep	5,703,057	12/1997	JOHNSTON			
	ep	5,705,151	01/1998	DOW			
	eq	5,718,914	02/1998	FOLDVARI			
	er	5,720,948	02/1998	BRUCKS			
	es	5,722,397	03/1998	EPPSTEIN			
	et	5,723,114	03/1998	THORNFELDT			
	eu	5,731,303	03/1998	HSIEH			
	ev	5,733,572	03/1998	UNGER			
	ew	5,733,762	03/1998	MIDOUX			
VH	ex	5,736,154	04/1998	FUISZ			
	ey	5,736,392	04/1998	HAWLEY-NELSON			
	ez	5,736,524	04/1998	CONTENT			

FOREIGN PATENT DOCUMENTS								English Abstract		Translation Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass				
								Enclosed	No	Enclose	No

OTHER (including in this order Author, Title, Periodical Name, Date, Page Number, etc.):

Examiner: *[Signature]* Date Considered: *6/20/05*

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

056707-5001-01

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Page 6 of 19

Examiner: Not Assigned Group Art Unit: 1645

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
UP	fa 5,738,647	04/1998	BERNHARD			
	fb 5,739,118	04/1998	CARRANO			
	fc 5,741,510	04/1998	ROLF			
	fd 5,756,117	05/1998	D'ANGELO			
	fe 5,760,098	06/1998	THORNFELDT			
	ff 5,766,899	06/1998	KUO			
	fg 5,770,580	06/1998	LEDLEY			
	fh 5,773,022	06/1998	NYQVIST-MAYER			
	fi 5,780,050	07/1998	JAIN			
	fj 5,783,567	07/1998	HEDLEY			
	fk 5,789,230	08/1998	COTTON			
	fl 5,804,214	09/1998	WONG			
	fm 5,804,566	09/1998	CARSON			
	fn 5,811,406	09/1998	SZOKA			
	fo 5,814,599	09/1998	MITRAGOTRI			
	fp 5,814,617	09/1998	HOFFMAN			
	fq 5,824,538	10/1998	BRANSTROM			
	fr 5,827,703	10/1998	DEBS			
	fs 5,827,705	10/1998	DEAN			
	ft 5,830,876	11/1998	WEINER			
	fu 5,830,877	11/1998	CARSON			
	fv 5,834,010	11/1998	QUAN			
	fw 5,837,289	11/1998	GRASELA			
	fx 5,837,533	11/1998	BOUTIN			
	fy 5,840,059	11/1998	MARCH			
	fz 5,843,913	12/1998	LI			

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						Enclose	No

OTHER (including in this order: Author, Title, Periodical Name, Date, Page Number, etc.)

Examiner

Date Considered: 6/20/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.  
Dkt. No.

Client Ref. No.

056707-5001-01

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assign. Group Art Unit: 1645

Page 7 of 169

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
UK	ga 5,844,107	12/1998	HANSON			
	gb 5,846,540	12/1998	RESTIFO			
	gc 5,846,949	12/1998	WAGNER			
	gd 5,849,719	12/1998	CARSON			
	ge 5,853,751	12/1998	MASIZ			
	gf 5,856,187	01/1999	RESTIFO			
	gg 5,858,784	01/1999	DEBS			
	gh 5,866,553	02/1999	DONNELLY			
	gi 5,877,159	03/1999	POWELL			
	gj 5,877,302	03/1999	HANSON			
	gk 5,885,971	03/1999	GERMAN			
	gl 5,910,306	06/1999	ALVING			
	gm 5,910,488	06/1999	NABEL			
	gn 5,914,114	06/1999	CASSELLS			
	go 5,916,879	06/1999	WEBSTER			
	gp 5,935,838	08/1999	ASKELOEF			
	gq 5,961,979	10/1999	SRIVASTAVA			
	gr 5,980,898	11/1999	GLENN			
	gs 5,985,847	11/1999	CARSON			
	gt 6,008,200	12/1999	KRIEG			
	gu 6,039,969	03/2000	TOMAI			
	gv 6,087,341	07/2000	KHAVARI			
	gw 6,173,202	01/2001	EPPSTEIN			
	gx 6,180,136	01/2001	LARSON			
	gy 6,183,434	02/2001	EPPSTEIN			
	gz 6,210,672	04/2001	COWING			

**FOREIGN PATENT DOCUMENTS**

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						Enclose	No

OTHER (including in this order: Author, Title, Periodical Name, Date, Page No., etc.)

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Examiner: Not Assigned	Group Art Unit 1645
------------------------	---------------------

## Page 8 of 1419

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)

[illegible]

OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Date Considered: 6/20/03

30185091v1

Atty.  
Dkt. No.

056707-5001-01

Client Ref.

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicants: GLENN et al.

Appl. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned Group Art Unit 1645

Page 9 of 14/14

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
-------------------------	--------------------	-----------------	---	-------	--------------	---------------------------------

**FOREIGN PATENT DOCUMENTS**

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						Enclose	No

**OTHER (including in this order: Author, Title, Periodical Name, Date, Reprint, Pages, etc.)**

ia	ALLISON "Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding" Arch Biochem Biophys 365 (1999) 289-298
ib	ALLISON "Optimization of storage stability of lyophilized actin using combinations of disaccharides and dextran" J Pharm Sci 89 (2000) 199-214
ic	ANDYA "The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody" Pharm Res 16 (1999) 350-358
id	ARAKAWA "Protein-solvent interactions in pharmaceutical formulations" Pharma Res 8 (1991) 285-291
ie	ARANY "Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (imiquimod) in genital warts" Antimicrob Agents Chemother 44 (2000) 1869-1873
if	ALVING "Effectiveness of liposomes as potential carriers of vaccines: Applications to cholera toxin and human malaria sporozoite antigen" Vaccine 4 (1986) 166-172
ig	ALVING "Liposomes as carriers of antigens and adjuvants" J Immunol Methods 140 (1991) 1-13
ih	ALVING "Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants" Immunobiology 187 (1993) 430-446
ii	ALVING "Novel adjuvant strategies for experimental malaria and AIDS vaccines" Ann NY Acad Sci 690 (1993) 265-275
ij	ALVING "The preparation and use of liposomes in immunological studies" In: Liposome Technology, vol. 3, CRC Press (1993) pp. 317-343
ik	ALVING "Cytotoxic T lymphocytes induced by liposomal antigens: Mechanisms of immunological presentation" AIDS Res Hum Retroviruses 10 suppl 2 (1994) S91-S94
il	ALVING "Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides" Immunol Rev 145 (1995) 5-31
im	BECKER "Mechanism in allergic contact dermatitis" Exp Dermatol 2 (1993) 63-69
in	BIRCH "Trehaloses" Adv Carb Chem Biochem 18 (1963) 201-2225
io	BLAUVELT "Human Langerhans cells express E-cadherin" J Invest Dermatol 104 (1995) 293-296
ip	BOS "The 500 dalton rule for the skin penetration of chemical compounds and drugs" Exp Dermatol 9 (2000) 165-169

Examiner

Date Considered: 6/20/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty. Dkt. No.	Mr.	Client Ref.
	056707-5001-01	

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicants: GLENN et al.

Appl. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assig.

Group Art Unit: 1645

Page 10 of 189

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
-------------------------	--------------------	-----------------	---	-------	--------------	---------------------------------

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No

OTHER (Including in this order: Author, Title, Periodical Name, Date, Reprint Pages, etc.)

ja	BOVSUN "DNA vaccine rubbed on skin provokes immune response" Biotechnol Newswatch (September 20, 1999) page 4
jb	BOWEN "Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens" Immunol 81 (1994) 338-342
jc	BUATES "Treatment of experimental Leishmaniasis with the immunomodulators imiquimod and S-28463: Efficacy and mode of action" J Infect Dis 179 (1999) 1485-1494
jd	CHEN "Induction of systemic immune responses in sheep by topical application of cholera toxin to skin" Vet Immunol Immunopathol 77 (2000) 191-199
je	CHIN "Antibody response against Pseudomonas aeruginosa membrane proteins in experimentally infected sheep" Vet Microbiol 43 (1995) 21-32
jf	CHIN "Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants" J Biotechnol 44 (1996) 13-19
gg	CONDON "DNA-based immunization by in vivo transfection of dendritic cells" Nature Med 2 (1996) 1122-1128
jh	COSTANTINO "Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone" J Pharm Sci 87 (1998) 1412-1420
ji	CRAIG "Cutaneous responses to cholera skin toxin in man. I. Responses in unimmunized American males" J Infect Dis 125 (1972) 203-215
jj	DE HAAN "Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice" Vaccine 13 (1995) 1320-1324
jk	EGBARIA "Liposomes as topical drug delivery system" Adv Drug Delivery Rev 5 (1990) 287-300
jl	ENK "An essential role for Langerhans cell-derived IL-1 beta in the initiation of primary immune responses in skin" J Immunol 151 (1993) 2390-2398
jm	FAN "Immunization via hair follicles by topical application of naked DNA to normal skin" Nature Biotechnol 17 (1999) 870-872
jn	FLEISHER "Topical delivery of growth hormone releasing peptide using liposomal systems: An in vitro study using hairless mouse skin" Life Sci 57 (1995) 1293-1297
jo	FRANK "Long-term stabilization of biologicals" Bio/Technology 12 (1994) 253-256

Examiner

Date Considered: 6/20/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty. Dkt. No.	Client Ref.
056707-5001-01	

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**


Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned Group Art Unit: 1645

Page 11 Of 14,9

U.S. PATENT DOCUMENTS										
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)				
FOREIGN PATENT DOCUMENTS							English Abstract	Translation Readily Available		
	Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	Enclosed	No	Enclose	No
OTHER (including in this order: Author, Title, Periodical Name, Date, Period, Pages, etc.):										
	ka	GEKKO "Mechanism of protein stabilization by glycerol: Preferential hydration in glycerol-water mixtures" Biochemistry 20 (1981) 4667-4676								
	kb	GLENN "Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A" Immunol Lett 47 (1995) 73-78								
	kc	GLENN "Skin immunization made possible by cholera toxin" Nature 391 (1998) 851								
	kd	GLENN "Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge" J Immunol 161 (1998) 3211-3214								
	ke	GLENN "Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants" Infect Immun 67 (1999) 1100-1106								
	kf	GLENN "Transcutaneous immunisation" Exp Opin Invest Drugs 8 (1999) 797-805								
	kg	GLENN "Transcutaneous immunization" In: <i>The Jordan Report 2000</i> , NIAID, pp. 91-93								
	kh	GLENN "Transcutaneous immunization: A human vaccine delivery strategy using a patch" Nature Med 6 (2000) 1403-1406								
	ki	GLENN "Transcutaneous immunization" In: <i>Vaccine Adjuvants</i> , Humana Press (April 2000) pp. 315-326								
	kj	GLENN "Transcutaneous immunization" In: <i>New Vaccine Technologies</i> , Landes Biosciences (June 2001) pp. 292-304								
	kk	GOODNOW "Chance encounters and organized rendezvous" Immunol Rev 156 (1997) 5-10								
	kl	GUPTA "Adjuvants for human vaccines - current status, problems and future prospects" Vaccine 13 (1995) 1263-1276								
	km	HAMMOND "Transcutaneous immunization of domestic animals: Opportunities and challenges" Adv Drug Delivery Rev 43 (2000) 45-55								
	kn	HAMMOND "Transcutaneous immunization: T cell responses and boosting of existing immunity" Vaccine 19 (2001) 2701-2707								
	ko	HANSON "Introduction to formulation of protein pharmaceuticals" In: <i>Stability of Protein Pharmaceuticals</i> , Plenum (1992) pp. 209-233								
	kp	HOELZLE "Increased accumulation of trehalose in rhizobia cultured under 1% oxygen" Appl Environ Microbiol 56 (1990) 3213-3215								
<div style="display: flex; justify-content: space-between;"> <div>Examiner: </div> <div>Date Considered: 6/20/05</div> </div>										
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>										

Atty. Dkt. No.	MM/YY	Client Ref.
	056707-5001-01	

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicants: GLENN et al.
Appln. No. 10/790,715
Filing Date: March 3, 2004
Examiner: Not Assign. Group Art Unit: 1645

Page 12 Of 149

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
-------------------------	--------------------	-----------------	---	-------	--------------	---------------------------------

**FOREIGN PATENT DOCUMENTS**

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No

**OTHER (including in this order: Author, Title, Periodical Name, Date, Relevance, Pages, etc.)**

1a	HSIUNG <i>Diagnostic Virology 3<sup>rd</sup> Ed.</i> , Yale Univ. Press (1982) pp. 29-34
1b	IIZUKA "Two simple methods for the evaluation of topically active anti-inflammatory steroidal ointments" <i>Agents Actions</i> 11 (1981) 254-259
1c	IZUTSU "Increased stabilizing effects of amphiphilic excipients on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices" <i>Pharm. Res</i> 12 (1995) 838-843
1d	JOHNSON "Vaccination onto bare skin" <i>Nature</i> 388 (1997) 729-730
1e	KAHAN "Immunosuppressive therapy" <i>Current Opin Immunol</i> 4 (1992) 553-560
1f	KNOP "Cellular and molecular mechanisms in the induction phase of contact sensitivity" <i>Intl Arch Allergy Immunol</i> 107 (1995) 231-232
1g	KORTING "Topical liposome drugs to come: what the patent literature tells us" <i>J Am Acad Dermatol</i> 25 (1991) 1068-1071
1h	KORTING "Interaction of liposomes with human epidermis reconstructed in vitro" <i>Br J Dermatol</i> 132 (1995) 571-579
1i	KOSECKA "Pertussis toxin stimulates hypersensitivity and enhances nerve-mediated antigen uptake in rat intestines" <i>Am J Physiol</i> 267 (1994) G745-G752
1j	LANE "In vitro-evaluation of human lymphocyte function" In: <i>Handbook of Experimental Immunology 4<sup>th</sup> Ed.</i> , vol. 2, Blackwell (1986) pp. 66.5-66.7
1k	LUO "Synthetic DNA delivery systems" <i>Nature Biotechnol</i> 18 (2000) 33-37
1l	MAHMOUD "Parasitic protozoa and helminths: Biological and immunological challenges" <i>Science</i> 246 (1989) 1015-1022
1m	MARINARO "Mucosal effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4" <i>J Immunol</i> 155 (1995) 4621-4629
1n	MENGIARDI "Virosomes as carriers for combined vaccines" <i>Vaccine</i> 13 (1995) 1306-1315
1o	MEZER "Liposomes - a selective drug delivery system for the topical route of administration. Lotion dosage form" <i>Life Sci</i> 26 (1980) 1473-1477
1p	MOGHIMI "Current progress and future prospects of liposomes in dermal drug delivery" <i>J Microencapsul</i> 10 (1993) 155-162
1q	NORIMATSU "Effects of aluminum adjuvant on systemic reactions of lipopolysaccharides in swine" <i>Vaccine</i> 13 (1995) 1325-1329

Examiner	Date Considered: 6/20/05
----------	--------------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Applicants: GLENN et al.**

Appln. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned	Group Art Unit: 1645
------------------------	----------------------

Page 13 of 1419

## U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS	English Abstract	Translation Readily
--------------------------	---------------------	------------------------

OTHER	Included in this order	Author Title Periodical Name Date Permalink Pages etc.

OTHER (including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner [Signature] Date Considered: 6/20/05

30185091v1

Atty. Dkt. No.	056707-5001-01	Client Ref.
-------------------	----------------	-------------

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned Group Art Unit: 1645

Page 14 of 189

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
-------------------------	--------------------	-----------------	---	-------	--------------	---------------------------------

**FOREIGN PATENT DOCUMENTS**

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No

**OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

na	STEINMAN "Dendritic cells in the T-cell areas of lymphoid organs" Immunol Rev 156 (1997) 25-37
nb	STINGL "The immune functions of epidermal cells" Immunol Ser 46 (1989) 3-72
nc	SUZUKI "Imiquimod, a topical immune response modifier, induces migration of Langerhans cells" J Invest Dermatol 114 (2000) 135-141
nd	UDEY "Cadherins and Langerhans cell immunobiology" Clin Exp Immunol 107 suppl 1 (1997) 6-8
ne	VASSELL "Activation of Langerhans cells following transcutaneous immunization" 13 FASEB J (1999) A633
nf	VERMA "Phagocytosis of liposomes by macrophages: intracellular fate of liposomal malaria antigen" Biochim Biophys Acta 1066 (1991) 229-238
ng	VERMA "Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages" Infect Immun 60 (1992) 2438-2444
nh	VUTLA "Transdermal iontophoretic delivery of enkephalin formulated in liposomes" J Pharm Sci 85 (1996) 5-8
ni	WALKER "The role of percutaneous penetration enhancers" Adv Drug Delivery Rev 18 (1996) 295-301
nj	WANG "Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine" J Immunol 154 (1995) 2784-2793
nk	WANG "Epicutaneous exposure of protein antigen induces a predominant Th2-like response with high IgE production in mice" J Immunol 156 (1996) 4077-4082
nl	WASSEF "Liposomes as carriers for vaccines" Immunomethods 4 (1994) 217-222
nm	WEINER "Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model" Antimicrob Agents Chemotherap 33 (1989) 1217-1221
nn	WHITE "Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes" Vaccine 11 (1993) 1341-1346
no	WHITE "Antibody and cytotoxic T-lymphocyte responses to a single liposome associated peptide antigen" Vaccine 13 (1995) 1111-1122
np	YASUTOMI "A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge" J Virol 69 (1995) 2279-2284
nq	ZELLMER "Interaction of phosphatidylcholine liposomes with the human stratum corneum" Biochim Biophys Acta 1237 (1995) 176-182

Examiner

Date Considered: 6/20/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)  <b>PTO Form 1449</b>	Attorney Docket No. <b>056707-5001-01</b>	Parent Application No. <b>10/790,715</b>
Applicants: Gregory M Glenn <i>et al.</i>		Page 15 of 19
Filing Date: March 3, 2004		Group Art Unit: 1645

### U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
<div style="font-size: 2em; text-align: center;">X</div>	Y1	3,964,482	06/1976	GERSTEL		
	Y2	4,775,361	10/1988	JACQUES		
	Y3	4,810,499	03/1989	NUWAYSER		
	Y4	5,003,987	04/1991	GRINWALD		
	Y5	5,133,970	07/1992	PETEREIT		
	Y6	5,182,109 C1	10/2001	TAMURA		
	Y7	5,250,023	10/1993	LEE		
	Y8	5,279,544	01/1994	GROSS		
	Y9	5,688,523	11/1997	GARBE		
	Y10	5,879,326	03/1999	GODSHALL		
	Y11	5,885,211	03/1999	EPPSTEIN		
	Y12	5,993,849	11/1999	ASSMUS		
	Y13	5,993,852	11/1999	FOLDVARI		
	Y14	6,019,982	02/2000	CLEMENTS		
	Y15	6,022,316	02/2000	EPPSTEIN		
	Y16	6,033,673	03/2000	CLEMENTS		
	Y17	6,033,684	03/2000	NORCIA		
	Y18	6,063,399	05/2000	ASSMUS		
	Y19	6,090,790	07/2000	ERIKSSON		
	Y20	6,142,939	11/2000	EPPSTEIN		
	Y21	6,149,919	11/2000	DOMENIGHINI		
	Y22	6,165,458	12/2000	FOLDVARI		
	Y23	6,165,500	12/2000	CEVC		
	Y24	6,190,367	02/2001	HALL		
	Y25	6,190,689	02/2001	HOFFMAN		
	Y26	6,207,184	03/2001	IKEDA		
	Y27	6,256,533	07/2001	YUZHAKOV		
	Y28	6,290,991	09/2001	ROSER		
	Y29	6,312,612	11/2001	SHERMAN		

### FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub Class	Translation Yes No

### OTHER DOCUMENTS

--	--	--	--	--	--	--	--	--	--

Examiner:	Date Considered: <u>6/20/05</u>
-----------	---------------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket No.  
056707-5001-01

Parent Application No.  
10/790,715

Applicants: Gregory M Glenn *et al.*

Page 16 of 19

Filing Date:  
March 3, 2004

Group Art Unit: 1645

## U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
UP	Y30	6,331,266	12/2001	POWELL			
	Y31	6,331,310	12/2001	ROSER			
	Y32	6,334,856	01/2002	ALLEN			
	Y33	6,348,212	02/2002	HYMES			
	Y34	6,348,450	02/2002	TANG			
	Y35	6,365,178	04/2002	VENKATESHWARAN			
	Y36	6,379,324	04/2002	GARTSTEIN			
	Y37	6,406,705	06/2002	DAVIS			
	Y38	6,413,523	07/2002	CLEMENTS			
	Y39	6,440,096	08/2002	LASTOVICH			
	Y40	6,451,240	09/2002	SHERMAN			
UP	Y41	6,454,755	09/2002	GODSHALL			
	Y42	6,471,903	10/2002	SHERMAN			

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes	No
UP	Y43	WO 95/17211	06/1995	WIPO				
UP	Y44	WO 96/06627	03/1996	WIPO				
UP	Y45	WO 96/19976	04/1996	WIPO				
UP	Y46	WO 96/37256	11/1996	WIPO				
UP	Y47	WO 97/04832	02/1997	WIPO				
UP	Y48	WO 97/07734	03/1997	WIPO				
UP	Y49	WO 98/00193	01/1998	WIPO				
UP	Y50	WO 98/29134	07/1998	WIPO				
UP	Y51	WO 99/13915	03/1999	WIPO				
UP	Y52	WO 99/26662	06/1999	WIPO				
UP	Y53	WO 99/47164	09/1999	WIPO				
UP	Y54	WO 99/47165	09/1999	WIPO				
UP	Y55	WO 99/47167	09/1999	WIPO				
UP	Y56	WO 99/61078	12/1999	WIPO				
UP	Y57	WO 00/33812	06/2000	WIPO				
UP	Y58	WO 00/74714	12/2000	WIPO				

## OTHER DOCUMENTS

Examiner:

Date Considered:

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
(Use several sheets if necessary)				Applicants: Gregory M Glenn <i>et al.</i> <span style="float: right;">Page 17 of 19</span>			
PTO Form 1449				Filing Date: March 3, 2004		Group Art Unit: 1645	

U.S. PATENT DOCUMENTS								
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date	


  

FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Sub Class	Translation Yes No	
<i>UPK</i>	Y59	WO 00/74763 A2	12/2000	WIPO				
<i>UPK</i>	Y60	WO 00/74763 A3	12/2000	WIPO				
<i>UPK</i>	Y61	WO 00/74766	12/2000	WIPO				
<i>UPK</i>	Y62	WO 01/34185	05/2001	WIPO				
<i>UPK</i>	Y63	WO 01/90758	11/2001	WIPO				
<i>UPK</i>	Y64	WO 02/02179	01/2002	WIPO				
<i>UPK</i>	Y65	WO 02/05889	01/2002	WIPO				
<i>UPK</i>	Y66	WO 02/07813	01/2002	WIPO				
<i>UPK</i>	Y67	WO 02/64162	08/2002	WIPO				
<i>UPK</i>	Y68	WO 02/64193	08/2002	WIPO				
<i>UPK</i>	Y69	WO 02/74244	09/2002	WIPO				

OTHER DOCUMENTS		
<i>UPK</i>	Y70	BECKER "Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs) - A novel approach to the protection of human" Virus Genes 9 (1994) 33-45
<i>UPK</i>	Y71	BECKER "An analysis of the role of skin Langerhans cells (LC) in the cytoplasmic processing of HIV-1 peptides after "peplotion" transepidermal transfer and HLA class I presentation to CD8+ CTLs - An approach to immunization of humans" Virus Genes 9 (1995) 133-147
<i>UPK</i>	Y72	CASTLE "Clinical relevance of age-related immune dysfunction" Clin Infect Dis 31 (2000) 578-585
<i>UPK</i>	Y73	CHEN "Adjuvation of epidermal powder immunization" Vaccine 19 (2001) 2908-2917
<i>UPK</i>	Y74	CHEN "Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization" J Virol 75 (2001) 7956-7965
<i>UPK</i>	Y75	EL-GHORR "Transcutaneous immunization with herpes simplex virus stimulates immunity in mice" FEMS Immunol Med Microbiol 29 (2000) 255-61
<i>UPK</i>	Y76	FENG "P55, an immunogenic but nonprotective 55-kilodalton Borrelia burgdorferi protein in murine Lyme disease" Infect Immun 64 (1996) 363-365
Examiner: <i>UPK</i>		Date Considered: 6/20/05

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
(Use several sheets if necessary)				Applicants: Gregory M Glenn <i>et al.</i> Page 18 of 19			
PTO Form 1449				Filing Date: March 3, 2004		Group Art Unit: 1645	
<b>U.S. PATENT DOCUMENTS</b>							
*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date	
<b>FOREIGN PATENT DOCUMENTS</b>							
Document Number	Date	Country	Class	Sub Class	Translation Yes No		
<b>OTHER DOCUMENTS</b>							
Y77	GLUECK "Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine <i>Escherichia coli</i> heat-labile toxin as a mucosal adjuvant" J Infect Dis 181 (2000) 1129-1132						
Y78	GOCKEL "Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract" Mol Immunol 37 (2000) 537-544						
Y79	HAGIWAR "Effectiveness and safety of mutant <i>Escherichia coli</i> heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine" Vaccine 19 (2001) 2071-2079						
Y80	HAGIWARA "Effects of intranasal administration of cholera toxin (or <i>Escherichia coli</i> heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain" 19 Vaccine (2001) 1652-1660						
Y81	HIOE "Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides" Vaccine 14 (1996) 412-418						
Y82	JANEWAY Immunobiology (1994) 10:78-10:79						
Y83	KALBITZ "Modulation der wirkstoffpenetration in die haut" Pharmazie 51 (1996) 619-637						
Y84	KATOH "Acute cutaneous barrier perturbation induces maturation of Langerhans' cells in hairless mice" Acta Derm Venereol 77(1997) 65-69						
Y85	KUMAMOTO "Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine" Nat Biotechnol 20 (2002) 64-69						
Y86	LIU "Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses" Vaccine 20 (2001) 42-48						
Y87	LU "Mutant <i>Escherichia coli</i> heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine" Vaccine 20 (2002) 1019-1029						
Y88	MURPHY "Antigen-Induced Protective and Nonprotective Cell-Mediated Immune Components against <i>Cryptococcus neoformans</i> " Infect Immun 66 (1998) 2632-2639						
Examiner: 				Date Considered: 6/20/05			
Examiner: (Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

<b>INFORMATION DISCLOSURE STATEMENT</b>				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
(Use several sheets if necessary)				Applicants: Gregory M Glenn <i>et al</i>			
PTO Form 1449				Filing Date: March 3, 2004		Page 19 of 19 Group Art Unit: 1645	
<b>U.S. PATENT DOCUMENTS</b>							
*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date	
Y89	5,910,306	08/1999	Glenn				
Y90	5,980,898	11/1999	Glenn				
Y91	6,797,276	02/1999	Glenn				
<b>FOREIGN PATENT DOCUMENTS</b>							
Document Number	Date	Country	Class	Sub Class	Translation Yes No		
Y92	1061951	02/99	EP				
<b>OTHER DOCUMENTS</b>							
Y93	OCKENHOUSE "Sequestrin, a CD36 recognition protein on <i>Plasmodium falciparum</i> malaria-infected erythrocytes identified by anti-idiotypic antibodies" Proc Natl Acad Sci 88 (1991) 3175-3179						
Y94	OGRA "Vaccination strategies for mucosal immune responses" Clin Microbiol Rev 14 (2001) 430-445						
Y95	PODDA "The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine" Vaccine 19 (2001) 2673-2680						
Y96	WILLIAMS "Skin absorption enhancers" Critical Rev in Therapeutic Drug Carrier Systems 9 (1992) 305-353						
Y97	TAKIGAWA "Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis" Ann N Y Acad Sci 941 (2001) 139-146						
Y98	TANG "Vaccination onto bare skin" Nature 388 (1997) 729-730						
Y99	"Tuberculin, Purified protein Derivative, Tine Test" Physician's desk Reference, 3 pages (2001)						
Y100	WATABE "Protection against influenza virus challenge by topical application of influenza DNA vaccine" Vaccine 14 (2001) 4434-4444						
Examiner:		Date Considered:					
		6/20/05					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							